Objective: To explore the application of antiemetic drugs in chemotherapy for patients with non-small cell lung cancer( NSCLC ), thus to give reference for rational applications of antiemetic drug during chemotherapy. Methods: 147 cases of non-small cell lung cancer patients in our hospital from June 2010 to June 2011 who accepted antiemetic drugs in their first chemotherapy were retrospectively analyzed. Results: The main antiemetic used during the chemotherapy was 5-hydroxytryptamine serotonin receptor-3 ( 5-HT3 ) antagonist, among which ondansetron was the most widely used one, with the drug use frequency ( DDDs ) of 2 306. 9 per year. The antiemetic drug was commonly applied with one kind( 53. 06% ). The regimen composed of two kinds of antiemetics accounts 38. 09% which was mainly consisted of ondansetron and tropisetron. The regimen composed of three kinds of antiemetics accounts 8.84%. Only 16.33% of the antiemetic drug applications met the requirement of National Comprehensive Cancer Network ( NCCN2011 ) Antiemetic Clinical Treatment Guidelines. The incidence of vomiting in all cases was as high as 76. 87%. Conclusion: The using of antiemetic drugs are not good enough in our hospital compared with the Guidelines and incidence of vomiting are higher when high-risk emetogenic chemotherapy drugs are used. The standard management and training of the application of antiemetic drugs should be emphasized.%目的:了解非小细胞肺癌(NSCLC)患者化疗过程中止吐药应用情况,为化疗期间止吐药物规范应用提供参考.方法:随机抽取我院2010年6月～2011年6月所有临床科室共147例首次化疗的NSCLC患者止吐药应用情况.结果:NSCLC患者化疗期间止吐药主要为5-羟色胺受体(5-HT3)拮抗剂,其中昂丹司琼应用最多,其年度用药频率(DDDs)为2306.9.止吐药以一联使用为主,占53.06%;二联使用占38.09%,主要为昂丹司琼+托烷司琼;三联使用占8.84%.我院止吐药应用方案符合美国国家综合癌症网络(NCCN2011)止吐治疗指南的比例仅为16.33%,所有病例呕吐发生率高达76.87%.结论:我院NSCLC患者化疗期间止吐药应用不够规范,高致吐风险化疗药物的呕吐发生率较高,应加强止吐药使用规范化管理和培训.
展开▼
